^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    trastuzumab rezetecan (SHR-A1811)

    i
    Other names: SHR-A1811, SHRA1811, SHR A1811, SHR-1811, SHR1811, SHR 1811
    Company:
    Glenmark, Jiangsu Hengrui Pharma
    Drug class:
    Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate
    Related drugs:
    2d
    Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC (clinicaltrials.gov)
    P=N/A, N=60, Not yet recruiting, The First Affiliated Hospital of Guangzhou Medical University
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification • HER-2 mutation
    |
    Perjeta (pertuzumab) • trastuzumab rezetecan (SHR-A1811)
    3d
    Trastuzumab rezetecan alone or in combination with adebrelimab in advanced solid tumors with HER2 expression or mutation: a prospective, multicenter, open, nonrandomized, multicohort study. (ChiCTR2500113763)
    P=N/A, N=200, Not yet recruiting, The Affiliated Hospital of Xuzhou Medical University; The Affiliated Hospital of Xuzhou Medical University
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 mutation • HER-2 expression
    |
    Herceptin (trastuzumab) • trastuzumab rezetecan (SHR-A1811) • AiRuiLi (adebrelimab)
    3d
    Trastuzumab rezetecan (SHR-A1811) combined with bevacizumab in previously treated HER2-altered non-small-cell lung cancer: a phase 2, single-arm study. (ChiCTR2500113565)
    P2, N=60, Not yet recruiting, Cancer Hospital Chinese Academy of Medical Science; Cancer Hospital Chinese Academy of Medical Sciences
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification • HER-2 mutation
    |
    Avastin (bevacizumab) • Herceptin (trastuzumab) • trastuzumab rezetecan (SHR-A1811)
    3d
    A randomized, controlled, multicenter clinical study of SHR-A1811 in combination with bevacizumab for second-line treatment of metastatic colorectal cancer. (ChiCTR2600116782)
    P2, N=80, Not yet recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene)
    |
    HER-2 overexpression • HER-2 expression
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • trastuzumab rezetecan (SHR-A1811) • leucovorin calcium
    3d
    SHR-A1811 plus QL1706 versus standard therapy as first-line treatment for locally advanced or metastatic HER2-overexpressing non-small cell lung cancer: an open-label, single-arm, phase II clinical trial (ChiCTR2500114106)
    P2, N=39, Not yet recruiting, Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    HER-2 positive • EGFR mutation • HER-2 overexpression • HER-2 mutation • ALK mutation • HER-2 positive + HER-2 overexpression
    |
    trastuzumab rezetecan (SHR-A1811) • Qibeian (iparomlimab/tuvonralimab)
    3d
    Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies: A Multicenter, Single-Arm, Phase II Study with Multiple Cohorts (ChiCTR2500112543)
    P2, N=90, Not yet recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • trastuzumab rezetecan (SHR-A1811)
    11d
    Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    New trial • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression • HER-2 underexpression
    |
    Herceptin (trastuzumab) • trastuzumab rezetecan (SHR-A1811)
    18d
    SHR-A1811(sc)-101: A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor (clinicaltrials.gov)
    P1, N=107, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    trastuzumab rezetecan (SHR-A1811)
    20d
    TAYLOR: Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer (clinicaltrials.gov)
    P2, N=200, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • Irene (pyrotinib) • albumin-bound paclitaxel • trastuzumab rezetecan (SHR-A1811)
    29d
    Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer (clinicaltrials.gov)
    P2, N=249, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 positive • HR positive • HER-2 expression • HER-2 underexpression
    |
    Herceptin (trastuzumab) • docetaxel • albumin-bound paclitaxel • cyclophosphamide • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiLi (adebrelimab)
    29d
    Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer (clinicaltrials.gov)
    P2, N=160, Recruiting, Fudan University | Not yet recruiting --> Recruiting | N=120 --> 160
    Enrollment open • Enrollment change
    |
    trastuzumab rezetecan (SHR-A1811) • SHR-A2102 • AiRuiLi (adebrelimab) • HRS-4642 • garetatug rezetecan (SHR-A1904)
    1m
    Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=45, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Herceptin (trastuzumab) • fulvestrant • trastuzumab rezetecan (SHR-A1811)